Compounds > albaconazole
Page last updated: 2024-12-08

albaconazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

albaconazole: UR-9825 is the (1R,2R)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID208952
CHEMBL ID298817
SCHEMBL ID1262830
MeSH IDM0290738

Synonyms (37)

Synonym
7-chloro-3-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)quinazolin-4(3h)-one
ur-9825
w-0027
albaconazole
7-chloro-3-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]quinazolin-4-one
CHEMBL298817
w0027 ,
187949-02-6
7-chloro-3-[(2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]quinazolin-4-one
albaconazol
4(3h)-quinazolinone, 7-chloro-3-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-
ur 9825
7-chloro-3-(2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)quinazolin-4(3h)-one
albaconazole [usan:inn]
unii-ydw24y8iab
ydw24y8iab ,
albaconazol [inn-spanish]
albaconazole (usan/inn)
D09702
(1r,2r)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2, 4-triazol-1-yl)propyl]quinazolin-4(3h)-one
(1r,2r)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]quinazolin-4(3h)-one
UHIXWHUVLCAJQL-MPBGBICISA-N
albaconazole [usan]
7-chloro-3-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]quinazolin-4(3h)-one
albaconazole [inn]
SCHEMBL1262830
DTXSID3058244
bdbm50011477
AKOS027327579
J-012103
DB12073
Q4708967
7-chloro-3-((2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)quinazolin-4(3h)-one
ur 9625; ur 9825
ur9825
w 0027
4(3h)-quinazolinone, 7-chloro-3-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-

Research Excerpts

Overview

Albaconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity. It has a remarkably long half-life in dogs, monkeys, and humans.

ExcerptReferenceRelevance
"Albaconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity and a remarkably long half-life in dogs, monkeys, and humans. "( Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Afonso, LC; Bahia, MT; Chiari, E; de Lana, M; Guedes, PM; Machado-Coelho, GL; Tafuri, WL; Urbina, JA; Veloso, VM, 2004)		2.03

Effects

ExcerptReferenceRelevance
"Albaconazole has also shown very potent activity against species of Candida, Cryptococcus and Aspergillus."( New and emerging treatments for fungal infections.
Denning, DW; Pasqualotto, AC, 2008)		1.07

Toxicity

ExcerptReferenceRelevance
" However, frequent repeated dosing is required, and hepatic and cardiac adverse events may occur."( A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
Malahias, S; Raterink, K; Sigurgeirsson, B; van Rossem, K, 2013)		0.59
" Most adverse events were mild or moderate, and treatment-related adverse events were all ≤3%."( A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
Malahias, S; Raterink, K; Sigurgeirsson, B; van Rossem, K, 2013)		0.59

Bioavailability

ExcerptReferenceRelevance
" Reduced toxicity, enhancement of bioavailability and counteraction of resistance are features desired by clinicians."( Newer antifungal agents.
Türel, O, 2011)		0.37

Dosage Studied

ExcerptRelevanceReference
" Its extended half-life probably permits dosing less frequently than once a day."( New and emerging treatments for fungal infections.
Denning, DW; Pasqualotto, AC, 2008)		0.35
" However, frequent repeated dosing is required, and hepatic and cardiac adverse events may occur."( A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
Malahias, S; Raterink, K; Sigurgeirsson, B; van Rossem, K, 2013)		0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)34.86000.00091.901410.0000AID1138338
Sterol 14-alpha demethylaseTrypanosoma cruzi strain CL BrenerIC50 (µMol)0.00100.00101.707010.0000AID1915709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (110)

Assay IDTitleYearJournalArticle
AID167736In vivo antifungal activity against systemic candidosis in rabbit kidney at a dose of 12.5 mg/kg, qd, po.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1651348Antifungal activity against fluconazole-resistant Candida albicans isolate 100 by NCCLS protocol based broth microdilution method2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID562993Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 5 mg/kg, administered through oral gavage once daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID432803Antifungal activity against Sporothrix albicans after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID725869Antifungal activity against Rhizomucor pusillus RHMI1 after 48 hrs by broth microdilution test2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID165452In vivo antifungal activity against systemic candidosis in rabbit lung at a dose of 2.5 mg/kg, qd, po.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID123517The compound was tested in vivo for anti-candida activity in mice model 1 (dose :0.5 mg/kg,fluconazole-treated group)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID562989Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 20 mg/kg, administered through oral gavage once daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID1247371Antifungal activity against Candida parapsilosis 22019 after 24 hrs by serial dilution method2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates.
AID307397Antifungal activity against Candida lusitaniae ATCC 42720 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID307400Antifungal activity against Aspergillus fumigatus ATCC 16424 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID118766In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/kg at various time intervals. (percent protection for 100% mortality with untreated group)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID307398Antifungal activity against Candida tropicalis ATCC 750 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID307394Antifungal activity against Candida glabrata ATCC 34138 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID725871Antifungal activity against Scedosporium sp. SCSP1 after 48 hrs by broth microdilution test2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID1651344Antifungal activity against Candida albicans Y0109 by NCCLS protocol based broth microdilution assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID167735In vivo antifungal activity against systemic candidosis in rabbit kidney at a dose of 0.5 mg/kg, qd, po.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID525140Antifungal activity against Fusarium moniliforme clade 2 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID725874Antifungal activity against Aspergillus fumigatus ASFU20 after 48 hrs by M38 method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID1138333Antimicrobial activity against fluconazole-resistant Candida albicans 100 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1247369Antifungal activity against Candida albicans SC5314 after 24 hrs by serial dilution method2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates.
AID220226In vitro for antifungal activity against 10 yeasts1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID562994Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 40 mg/kg, administered through oral gavage twice daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID562990Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 10 mg/kg, administered through oral gavage twice daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID1247374Antifungal activity against Aspergillus fumigatus 7544 after 48 hrs by serial dilution method2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates.
AID1138335Antimicrobial activity against fluconazole-resistant Candida albicans J18 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID725882Antifungal activity against Candida krusei CAKR7 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID563001Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 5 mg/kg, administered through oral gavage once daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID562987Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 40 mg/kg, administered through oral gavage once daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID307403Antifungal activity against Aspergillus niger ATCC 9042 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID1651345Antifungal activity against Candida parapsilosis 22019 by NCCLS protocol based broth microdilution assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID26407Half-life in rats after iv administration1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID432799Antifungal activity against Sporothrix brasiliensis after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID562998Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 10 mg/kg, administered through oral gavage twice daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID725881Antifungal activity against Candida krusei CAKR8 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID307399Antifungal activity against Candida parapsilosis ATCC 21019 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID432801Antifungal activity against Sporothrix globosa after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID195068In vivo activity against disseminated aspergillosis (liver) in immunocompromized rat model at a dose of 1 mg/kg, bid, po1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID73614In vitro antifungal activity against 6 filamentous fungi1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID562996Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 20 mg/kg, administered through oral gavage twice daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID563000Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 5 mg/kg, administered through oral gavage twice daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID118757In vivo antifungal activity against murine candidosis model after peroral administration with 0.25 mg/kg at various time intervals. (percent protection for 100% mortality with untreated group); not tested1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1138336Antimicrobial activity against fluconazole-resistant Candida albicans J28 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID725877Antifungal activity against Aspergillus fumigatus ASFU13 after 48 hrs by M38 method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID1651343Antifungal activity against Aspergillus fumigatus 7544 by NCCLS protocol based broth microdilution assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID1138338Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID118756In vivo antifungal activity against murine candidosis model after peroral administration with 0.25 mg/kg at various time intervals. (percent protection for 100% mortality with fluconazole-treated group.); not tested1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID432800Antifungal activity against Sporothrix schenckii after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID118758In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/Kg at various time intervals. (percent protection for 100% mortality with fluconazole-treated group.)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID562995Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 40 mg/kg, administered through oral gavage once daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID307401Antifungal activity against Aspergillus flavus ATCC MYA-1004 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID1247373Antifungal activity against Candida glabrata 537 after 24 hrs by serial dilution method2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates.
AID562988Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 20 mg/kg, administered through oral gavage twice daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID118893In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg at various time intervals. (percent protection for 100% mortality with untreated group)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID123519The compound was tested in vivo for anti-candida activity in mice model 2(dose: 5 mg/kg, untreated group).1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID525139Antifungal activity against Fusarium moniliforme clade 1 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1138337Antimicrobial activity against fluconazole-resistant Candida albicans J38 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1651341Antifungal activity against Candida albicans SC5314 by NCCLS protocol based broth microdilution assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID525141Antifungal activity against Fusarium moniliforme clade 3 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID562992Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 5 mg/kg, administered through oral gavage twice daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID525142Antifungal activity against Fusarium thapsinum by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1138330Antimicrobial activity against Cryptococcus neoformans 32609 after 72 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID195069In vivo activity against disseminated aspergillosis (liver) in immunocompromized rat model at a dose of 25 mg/kg, bid, po1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID725880Antifungal activity against Candida glabrata CAGL2 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID1247372Antifungal activity against Cryptococcus neoformans 32609 after 72 hrs by serial dilution method2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates.
AID123520The compound was tested in vivo for anti-candida activity in mice model 2(dose :5 mg/kg,fluconazole-treated group)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID123518The compound was tested in vivo for anti-candida activity in mice model 1(dose: 0.5 mg/kg, untreated group).1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID725886Antifungal activity against fluconazole-resistant Candida albicans DSY735 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID432802Antifungal activity against Sporothrix mexicana after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID1138331Antimicrobial activity against Candida glabrata 537 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1651342Antifungal activity against Cryptococcus neoformans 32605 by NCCLS protocol based broth microdilution assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID195070In vivo activity against disseminated aspergillosis (liver) in immunocompromized rat model at a dose of 5 mg/kg, bid, po1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID725878Antifungal activity against acquired-resistant Candida parapsilosis CAPA2 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID1651347Antifungal activity against Microsporum gypseum CMCC by NCCLS protocol based broth microdilution assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID725870Antifungal activity against Rhizomucor pusillus RHPU1 after 48 hrs by broth microdilution test2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID307395Antifungal activity against Candida krusei ATCC 6528 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID1247370Antifungal activity against Candida albicans Y0109 after 24 hrs by serial dilution method2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates.
AID307393Antifungal activity against Candida albicans ATCC 36082 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID1138340Aqueous solubility of the compound in hydrochloric acid solution at pH 1.22014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1651349Antifungal activity against fluconazole-resistant Candida albicans isolate 103 by NCCLS protocol based broth microdilution method2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID195071In vivo activity against disseminated aspergillosis (liver) in immunocompromized rat model at a dose of 50 mg/kg, bid, po1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID165450In vivo antifungal activity against systemic candidosis in rabbit lung at a dose of 0.5 mg/kg, qd, po.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID167737In vivo antifungal activity against systemic candidosis in rabbit kidney at a dose of 2.5 mg/kg, qd, po.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1138341Aqueous solubility of the compound in phosphate buffer at pH 7.42014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID562991Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 10 mg/kg, administered through oral gavage once daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID562997Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 20 mg/kg, administered through oral gavage once daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID725876Antifungal activity against Aspergillus fumigatus ASFU7 after 48 hrs by M38 method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID725873Antifungal activity against Aspergillus fumigatus ASFU19 after 48 hrs by M38 method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID563002Antifungal activity against Candida albicans isolate 03-2718 after 48 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID725875Antifungal activity against Aspergillus fumigatus ASFU17 after 48 hrs by M38 method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID165451In vivo antifungal activity against systemic candidosis in rabbit lung at a dose of 12.5 mg/kg, qd, po.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1138332Antimicrobial activity against Aspergillus fumigatus 7544 after 48 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1138328Antimicrobial activity against Candida albicans Y0109 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID1138334Antimicrobial activity against fluconazole-resistant Candida albicans 103 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID49099The compound was tested in vitro for antifungal activity against Candida albicans.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1138327Antimicrobial activity against Candida albicans SC5314 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID562999Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 10 mg/kg, administered through oral gavage once daily for 5 days measured on day 1 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID725885Antifungal activity against fluconazole-susceptible Candida albicans CAAL93 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID1138329Antimicrobial activity against Candida parapsilosis 22019 after 24 hrs by serial dilution method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID562986Antifungal activity against Candida albicans isolate 03-2718 infected BALB/c mouse vaginitis model assessed as reduction in fungal load in vagina at 40 mg/kg, administered through oral gavage twice daily for 5 days measured on day 6 post inoculation2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Efficacy of albaconazole against Candida albicans in a vaginitis model.
AID1915709Inhibition of Trypanosoma cruzi Sterol 14-alpha demethylase2021European journal of medicinal chemistry, Feb-05, Volume: 211Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
AID725872Antifungal activity against Aspergillus fumigatus ASFU23 after 48 hrs by M38 method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID307402Antifungal activity against Aspergillus terreus ATCC 28301by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID1651346Antifungal activity against Candida glabrata 537 by NCCLS protocol based broth microdilution assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.
AID118889In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg at various time intervals. (percent protection for 100% mortality with fluconazole-treated group.)1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID725883Antifungal activity against fluconazole-resistant Candida albicans DSY292 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID725884Antifungal activity against fluconazole-susceptible Candida albicans CAAL97 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID15872Log P value of the compound.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID307396Antifungal activity against Cryptococcus neoformans ATCC 21019 by broth microdilution assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Discovery of novel indazole-linked triazoles as antifungal agents.
AID725879Antifungal activity against acquired-resistant Candida parapsilosis CAPA1 after 24 hrs by spectrofluorometric analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (6.06)18.2507
2000's20 (60.61)29.6817
2010's9 (27.27)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.35 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index42.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.94%)5.53%
Reviews7 (20.59%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Randomized, Open-Label, Crossover Safety and Pharmacokinetic Study of 400 mg Albaconazole as a Tablet Formulation Versus a Capsule Formulation in Healthy Subjects [NCT01039883]Phase 140 participants (Actual)Interventional2009-11-23Completed
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis [NCT00730405]Phase 2582 participants (Actual)Interventional2008-07-16Completed
A Single-Blind, Randomized, Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis [NCT00199264]Phase 260 participants Interventional2004-06-30Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00730405 (6) [back to overview]Absolute Change in Unaffected Part of Target Nail From Baseline to Week 52
NCT00730405 (6) [back to overview]The Percentage of Participants Who Achieve Clinical Cure at Week 52
NCT00730405 (6) [back to overview]The Percentage of Participants Who Achieve Complete Cure at Week 52
NCT00730405 (6) [back to overview]The Percentage of Participants Who Achieve Effective Treatment at Week 52
NCT00730405 (6) [back to overview]The Percentage of Participants Who Achieve Mycological Cure at Week 52
NCT00730405 (6) [back to overview]The Percentage of Participants With a Global Change Score of Cleared or Much Improved at Week 52

Absolute Change in Unaffected Part of Target Nail From Baseline to Week 52

Length of the unaffected part of the target nail was measured in millimeters along the midpoint from the nail fold to the proximal border of the affected part (lowest point affected) along the midpoint of the target nail. It was assessed on Week 4, 8, 12, 16, 20, 24, 30, 36, 44 and 52. Baseline values were the observations at Week 0/Day 1 or before. Change from Baseline was a Baseline value subtracted from Week 52 value. P-value was based on analysis of variance (ANOVA) with treatment and pooled center. Statistics is provided for adjusted least square mean. (NCT00730405)
Timeframe: Baseline (Week 0/Day 1 or before) and up to Week 52

InterventionMillimeters (Mean)
Albaconazole 400 mg (36 Weeks) Oral Weekly6.47
Albaconazole 400 mg (24 Weeks) Oral Weekly6.21
Albaconazole 200 mg (36 Weeks) Oral Weekly4.75
Albaconazole 100 mg (36 Weeks) Oral Weekly3.78
Placebo0.40

[back to top]

The Percentage of Participants Who Achieve Clinical Cure at Week 52

At each study visit, the investigator assessed the percentage of affected toenail on the target nail by estimating the percent affected nail in each quadrant, summing the percent affected in each quadrant and dividing the sum by 4. Clinical cure was defined as 100% clear nail. It was assessed on Week 4, 8, 12, 16, 20, 24, 30, 36, 44 and 52. (NCT00730405)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Albaconazole 400 mg (36 Weeks) Oral Weekly34
Albaconazole 400 mg (24 Weeks) Oral Weekly32
Albaconazole 200 mg (36 Weeks) Oral Weekly30
Albaconazole 100 mg (36 Weeks) Oral Weekly16
Placebo1

[back to top]

The Percentage of Participants Who Achieve Complete Cure at Week 52

At each study visit, the investigator assessed the percentage of affected toenail on the target nail by estimating the percent affected nail in each quadrant, summing the percent affected in each quadrant and dividing the sum by 4. Complete cure was defined as mycological cure plus clinical cure. It was assessed on Week 4, 8, 12, 16, 20, 24, 30, 36, 44 and 52. (NCT00730405)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Albaconazole 400 mg (36 Weeks) Oral Weekly33
Albaconazole 400 mg (24 Weeks) Oral Weekly26
Albaconazole 200 mg (36 Weeks) Oral Weekly21
Albaconazole 100 mg (36 Weeks) Oral Weekly12
Placebo0

[back to top]

The Percentage of Participants Who Achieve Effective Treatment at Week 52

At each study visit, the investigator assessed the percentage of affected toenail on the target nail by estimating the percent affected nail in each quadrant, summing the percent affected in each quadrant and dividing the sum by 4. Effective treatment was defined as a mycological cure and clear or almost clear nail (distal subungual hyperkeratosis and/or onycholysis leaving less than 10% of nail plate effected). Comparisons were carried out in a sequential step-down fashion, combined with the Holm procedure at step 2. P-value was based on a sequential step-down combined with the Holm procedure. It was assessed on Week 4, 8, 12, 16, 20, 24, 30, 36, 44 and 52. (NCT00730405)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Albaconazole 400 mg (36 Weeks) Oral Weekly54
Albaconazole 400 mg (24 Weeks) Oral Weekly38
Albaconazole 200 mg (36 Weeks) Oral Weekly29
Albaconazole 100 mg (36 Weeks) Oral Weekly21
Placebo1

[back to top]

The Percentage of Participants Who Achieve Mycological Cure at Week 52

At each study visit, the investigator assessed the percentage of affected toenail on the target nail by estimating the percent affected nail in each quadrant, summing the percent affected in each quadrant and dividing the sum by 4. Mycological cure was defined as negative potassium hydroxide (KOH) and negative cultures for dermatophytes. It was assessed on Week 12, 16, 20, 24, 30, 36, 44 and 52. (NCT00730405)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Albaconazole 400 mg (36 Weeks) Oral Weekly71
Albaconazole 400 mg (24 Weeks) Oral Weekly54
Albaconazole 200 mg (36 Weeks) Oral Weekly43
Albaconazole 100 mg (36 Weeks) Oral Weekly34
Placebo6

[back to top]

The Percentage of Participants With a Global Change Score of Cleared or Much Improved at Week 52

A count of the number of toenails affected, using visual examination, was performed at all study visits (Week 12, 24, 30, 36, 44 and 52). The investigator given a global evaluation of the toenails condition, based on the investigator's assessment of the reduction in extent of nail involvement and improvement in clinical signs as compared with the status at the Baseline visit. The 0-5 rating scale was used: 0: cleared, 1: much improved, 2: minimally improved, 3: unchanged, 4: minimally worse and 5: much worse; where higher score indicates worse condition and lower score indicates clear toenail. (NCT00730405)
Timeframe: Week 52

InterventionPercentage of participants (Number)
Albaconazole 400 mg (36 Weeks) Oral Weekly71
Albaconazole 400 mg (24 Weeks) Oral Weekly62
Albaconazole 200 mg (36 Weeks) Oral Weekly61
Albaconazole 100 mg (36 Weeks) Oral Weekly45
Placebo10

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
menthol
Menthol: A monoterpene cyclohexanol produced from mint oils.		2.0210p-menthane monoterpenoid;
secondary alcohol		volatile oil component
alfuzosin
alfuzosin: structure given in first source		3.4110monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
bunazosin
bunazosin: structure		3.4110quinazolines
cisapride
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.		2.110benzamides
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		4.12150conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		2.7230aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
itraconazole
[no description available]		3.1450piperazines
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		3.4110aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		3.1350dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		3.4110chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		3.4110aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
terazosin
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia		3.4110furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		3.4110
methaqualone
Methaqualone: A quinazoline derivative with hypnotic and sedative properties. It has been withdrawn from the market in many countries because of problems with abuse. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methaqualone : A member of the class of quinazolines that is quinazolin-4-one substituted at positions 2 and 3 by methyl and o-tolyl groups respectively. A depressant that increases the activity of the GABA receptors in the brain and nervous system, it is used as a sedative and hypnotic medication. It became popular as a recreational drug and club drug in the late 1960s and 1970s.		3.4110quinazolinesGABA agonist;
sedative
2-methyltetrahydrofuran
2-methyltetrahydrofuran: structure in first source		2.1710
tetrahydrofuran
oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.		2.1710cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		9.46251azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
thiazoles
[no description available]		5.48801,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		2.0210C-nitro compound;
imidazoles		antitubercular agent
neodymium
Neodymium: An element of the rare earth family of metals. It has the atomic symbol Nd, atomic number 60, and atomic weight 144.24, and is used in industrial applications.		2.1710f-block element atom;
lanthanoid atom
proquazone
proquazone: nonsteroid anti-inflammatory agent; structure		3.4110pyrimidines
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.0210C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
etoposide
[no description available]		3.4110beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		2.9340aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		9.462511,2,3-triazole
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		8.98130conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
eberconazole
eberconazole : A racemate comprising equimolar amounts of (R)- and (S)-eberconazole. Used (as its nitrate salt) for topical treatment of superficial mycoses.. 1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole : A member of the class of dibenzannulenes that is 10,11-dihydrodibenzo[a,d][7]annulene carrying two chloro substituents at positions 2 and 4 as well as an imidazol-1-yl substituent at position 5.		2.0410dibenzannulene;
imidazoles;
organochlorine compound
gefitinib
[no description available]		3.4110aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
canertinib
[no description available]		3.4110monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
lapatinib
[no description available]		3.4110furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sm 8668
Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive		1.9910
ravuconazole
ER 30346: structure in first source. ravuconazole : A member of the class of triazoles that is 1-butyl-1H-1,2,4-triazole in which the butyl group is substituted at positions 2, 2, and 3 by hydroxy, 2,4-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively (the R,R stereoisomer). It exhibits antifungal activity by inhibition of 14alpha demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCIO4)		10.921301,3-thiazoles;
fluorobenzenes;
nitrile;
tertiary alcohol;
triazoles		antifungal drug;
antileishmanial agent;
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor
posaconazole
[no description available]		2.9440aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		2.4420antibiotic antifungal drug;
echinocandin		antiinfective agent
tak 187
TAK 187: structure in first source; ergosterol biosynthesis inhibitor with possible usage against Trypanosoma		3.520
efinaconazole
efinaconazole: an antifungal agent; structure in first source. efinaconazole : A member of the class of triazoles that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,4-difluorophenyl, and 4-methylenepiperidin-1-yl groups, respectively (the 2R,3R stereoisomer). It is an antifungal drug used for the topical treatment of onychomycosis (a nail infection caused mainly by dermatophytes).		2.1710conazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
glycosides
[no description available]		3.2710
terbinafine
[no description available]		2.9540acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		3.4270antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
nifurtimox
Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.		2.0210nitrofuran antibiotic
isavuconazole
isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.		9.7301,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug
zm 447439
ZM447439 : A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively.		3.4110aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor
ici 195739
ICI 195739: structure given in first source		3.110
linagliptin
Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.		3.4110aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
azd 1152
AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.		3.4110anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug
aminocandin
aminocandin: a lipopeptide belonging to the echinocandin class of antifungal compounds; inhibits glucan synthase. aminocandin : A member of the family of echinocandins that shows broad-spectrum in vitro activity against Aspergillus and Candida spp.		4.0720aromatic ether;
echinocandin;
homodetic cyclic peptide		antiinfective agent
mk-3118
ibrexafungerp: a glucan synthase inhibitor with antifungal activity; structure in first source		3.2710
t-2307
T-2307: antimalarial		3.2710
vt-1161
VT-1161: has antifungal activity		3.2710organic molecular entity
raltitrexed
[no description available]		3.4110N-acyl-amino acid
bl 4162a
anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.		3.4110imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Aspergillus Infection
[description not available]		03.3420
Candida Infection
[description not available]		02.4120
Aspergillosis
Infections with fungi of the genus ASPERGILLUS.		03.3420
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		02.4120
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Sporothrix brasiliensis Infection
[description not available]		02.0410
Sporotrichosis
The commonest and least serious of the deep mycoses, characterized by nodular lesions of the cutaneous and subcutaneous tissues. It is caused by inhalation of contaminated dust or by infection of a wound with SPOROTHRIX.		02.0410
Fungal Diseases
[description not available]		04.6740
Mycoses
Diseases caused by FUNGI.		04.6740
Vaginitis
Inflammation of the vagina characterized by pain and a purulent discharge.		07.0510
Benign Neoplasms
[description not available]		03.2310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.2310
Nail Fungus
[description not available]		04.3911
Foot Dermatoses
Skin diseases of the foot, general or unspecified.		04.3911
Onychomycosis
A fungal infection of the nail, usually caused by DERMATOPHYTES; YEASTS; or nondermatophyte MOLDS.		09.3911
Candidiasis, Invasive
An important nosocomial fungal infection with species of the genus CANDIDA, most frequently CANDIDA ALBICANS. Invasive candidiasis occurs when candidiasis goes beyond a superficial infection and manifests as CANDIDEMIA, deep tissue infection, or disseminated disease with deep organ involvement.		02.9810
Actinomycetoma
[description not available]		02.0110
Mycetoma
A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as MADURELLA fungi and bacteria ACTINOMYCETES, with different grain colors.		02.0110
Cerebral Cryptococcosis
[description not available]		02.0210
Meningitis, Cryptococcal
Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)		02.0210
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4220
American Trypanosomiasis
[description not available]		03.3320
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		03.3320
C gattii Infection
[description not available]		02.0210
Cryptococcosis
Fungal infection caused by genus CRYPTOCOCCUS.		02.0210
Candidiasis, Genital
[description not available]		02.0310
Candidiasis, Vulvovaginal
Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA.		02.0310